In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...
Its core business includes the development of devices for sleep apnea -- such as CPAP and APAP machines ... of digital solutions in homecare settings. ResMed’s adjusted gross margin improved ...
The great obesity drug scare of 2023 is now behind ResMed as evidence in the December quarter suggests GLP-1s are actually a positive for the sleep apnoea industry ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback